2. Search Result
Search Result
Results for "

SAMS

" in MedChemExpress (MCE) Product Catalog:

66

Inhibitors & Agonists

1

Fluorescent Dye

8

Peptides

5

Natural
Products

5

Isotope-Labeled Compounds

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0136
    SAMS
    2 Publications Verification

    		 AMPK Metabolic Disease
    SAMS peptide is a specific substrate for the AMP-activated protein kinase (AMPK).
    SAMS
  • HY-P0136AF
    FAM-SAMS TFA

    		Fluorescent Dye Others
    FAM-SAMS TFA is a 5-FAM (HY-66022) labeled SAMS (HY-P0136). SAMS peptide is a specific substrate for the AMP-activated protein kinase (AMPK) .
    FAM-SAMS TFA
  • HY-137247
    16-Mercaptopalmitic acid

    		Biochemical Assay Reagents Others
    16-Mercaptopalmitic acid is a chain alkylmercaptan with a long -CH2 group that forms a self-assembled monolayer (SAM) on a variety of substrates .
    16-Mercaptopalmitic acid
  • HY-124984
    ML353

    		mGluR Neurological Disease
    ML353 is a selective ligand of mGlu5 silent allosteric modulator (SAM) with an Ki value of 18.2 nM. ML353 improves the affinity of common allosteric sites, 20-fold higher than the previous mGlu5 SAM tool compound 5mpep. ML353 has potential applications in solving the intrinsic activity of SAM in vivo or as a agent blocker . ML353 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    ML353
  • HY-122559
    BMS-984923

    		mGluR Neurological Disease
    BMS-984923, a potent mGluR5 silent allosteric modulator (SAM), with exquisite binding affinity (Ki = 0.6 nM), exhibits good oral bioavailability and BBB penetration. BMS-984923 potently inhibits the PrPC-mGluR5 interaction and prevents pathological Aβo signaling without affecting physiological glutamate signaling .
    BMS-984923
  • HY-P0136F
    FAM-SAMS

    		AMPK Others
    FAM-SAMS is a 5-FAM (HY-66022) labeled SAMS (HY-P0136). SAMS peptide is a specific substrate for the AMP-activated protein kinase (AMPK) .
    FAM-SAMS
  • HY-163174
    II399

    		Amine N-methyltransferase Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases .
    II399
  • HY-116605
    GSK926

    		Histone Methyltransferase Cancer
    GSK926 (compound 3) is a selective histone lysine methyltransferase EZH2 inhibitor (IC50=0.02 μM; Ki=7.9 nM), with SAM-competitive and cell-active properties. GSK926 can be used in cancer research .
    GSK926
  • HY-107758
    Y-29794 oxalate

    		Prolyl Endopeptidase (PREP) Cancer
    Y-29794 oxalate is a selective, orally active and blood-brain barrier permeable non-peptide prolyl endopeptidase inhibitor. Y-29794 oxalate blocks the IRS1-AKT-mTORC1 pathway and inhibits tumor growth. Y-29794 oxalate is also effective in inhibiting the progression of Aβ-like deposition in the hippocampus of aging-accelerated mice (SAM) .
    Y-29794 oxalate
  • HY-155280
    SARS-CoV-2-IN-60

    		SARS-CoV Infection
    SARS-CoV-2-IN-60 (compound 5a) is an S-adenosylmethionine (SAM)-competitive and irreversible SARS-CoV-2 nsp16-nsp10 methyltransferase activity inhibitor with an IC50 of 9 μM and a Ki of 26 μM. SARS-CoV-2-IN-60 can specifically occupy a newly identified pocket adjacent to the SAM-binding site on nsp16. SARS-CoV-2-IN-60 has the potential for pan-coronavirus therapeutics .
    SARS-CoV-2-IN-60
  • HY-145778
    AGI-41998

    		Somatostatin Receptor Neurological Disease
    AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
    AGI-41998
  • HY-145777
    AGI-43192

    		Somatostatin Receptor Neurological Disease Cancer
    AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
    AGI-43192
  • HY-113786
    EZH2-IN-21

    		Histone Methyltransferase Cancer
    EZH2-IN-21 is a potent inhibitor of the histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) with anticancer activity. EZH2-IN-21 is competitive with the cofactor SAM and noncompetitive with peptide or nucleosome substrates .
    EZH2-IN-21
  • HY-157486
    KMI169

    		Epigenetic Reader Domain Cancer
    KMI169 is a potent and selective bi-substrate inhibitor targeting the SAM and substrate binding pockets of KMT9. KMT9 monomethylates histone H4 lysine 12 and controls the proliferation of prostate cancer cells. KMI169 can be used for the research of prostate cancer .
    KMI169
  • HY-162230
    PRMT5-IN-33

    		Apoptosis Histone Methyltransferase Cancer
    PRMT5-IN-33 (compound A8) is a selective, SAM-competitve PRMT5 inhibitors with IC50 of 10.9 nM. PRMT5-IN-33 induces apoptosis and inhibits proliferation of cells Z-138 and MOLM-13. PRMT5-IN-33 exhibits an antitumor activity .
    PRMT5-IN-33
  • HY-136145
    FIDAS-3

    		Wnt Cancer
    FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities .
    FIDAS-3
  • HY-136144
    FIDAS-5
    3 Publications Verification

    		 Methionine Adenosyltransferase (MAT) Cancer
    FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM. FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-5 has anticancer activities .
    FIDAS-5
  • HY-14334
    SAM-315

    WAY-255315

    		 5-HT Receptor Neurological Disease
    SAM-315 (WAY-255315) is a potent antagonist of 5-Hydroxytryptamine-6, with Ki and IC50 of 1.1 nM and 4.6 nM, respectively. SAM-315 significantly increases acetylcholine and glutamate release in hippocampus of the brain .
    SAM-315
  • HY-16938
    5'-Methylthioadenosine
    4 Publications Verification

    5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine

    		 Endogenous Metabolite Apoptosis Parasite Metabolic Disease Cancer
    5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .
    5'-Methylthioadenosine
  • HY-148904
    Allylic-SAM

    		Amine N-methyltransferase Others
    Allylic-SAM is an S-adenosyl methionine (SAM) analog for the enrichment and detection of methyltransferase target sites in RNA.
    Allylic-SAM
  • HY-P5891
    TAT-SAMβA

    		PKC Cardiovascular Disease
    TAT-SAMβA is the peptide consist of RNAENFDRF (SAMβA; HY-P3429) conjugated to the cell penetrating TAT protein-derived peptide TAT47–57. TAT-SAMβA is a selective antagonist of Mfn1-βIIPKC association. TAT-SAMβA protects mouse embryonic fibroblast cells (MEFs) against oxidative stress-induced cytotoxicity .
    TAT-SAMβA
  • HY-137802
    SAHO2

    S-Adenosyl-L-homocysteine sulfone

    		 Amino Acid Derivatives Others
    SAHO2 is the sulfone form of the methyl donor S-(5'-adenosyl)-L-methionine chloride (SAM) and serves as a substrate for radical SAM enzymes .
    SAHO2
  • HY-P3429
    SAMβA

    		PKC Cardiovascular Disease
    SAMβA is conjugated to the cell permeable peptide TAT47-57. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
    SAMβA
  • HY-P3429A
    SAMβA TFA

    		PKC Cardiovascular Disease
    SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats .
    SAMβA TFA
  • HY-14431
    Cerlapirdine
    1 Publications Verification

    SAM-531; PF-05212365

    		 5-HT Receptor Neurological Disease
    Cerlapirdine (SAM-531, PF-05212365) is a selective and potent full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine has the potential for researching the Alzheimer's disease .
    Cerlapirdine
  • HY-157116
    ICMT-IN-48

    		ICMT Cancer
    ICMT-IN-48 (compound 1) is an ICMT inhibitor that is competitive (Km=13 μM) for the prenylated methyl acceptor, the first substrate of ICMT. ICMT-IN-48 inhibits ICMT activity with IC50s affected by the concentration of the second substrate S-adenosylmethinine (SAM), and the IC50s are 3.5 μM (1×Km SAM) and 2.3 μM (10×Km SAM), respectively .
    ICMT-IN-48
  • HY-122595
    EZH2-IN-1

    		Histone Methyltransferase Cancer
    EZH2-IN-1 (compound 3) is a selective and SAM-competitive EZH2 and EZH1 inhibitor with an IC50s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research .
    EZH2-IN-1
  • HY-136541
    YB-0158
    2 Publications Verification

    Wnt pathway inhibitor 2

    		 Wnt Apoptosis Cancer
    YB-0158 (Wnt pathway inhibitor 2) is a reverse-turn peptidomimetic and a potent colorectal cancer stem cell (CSC) targeting agent. YB-0158 disrupts Sam68-Src interactions and induces apoptosis in CRC cells. Anti-cancer activities .
    YB-0158
  • HY-104009A
    GSK2807 Trifluoroacetate

    		Histone Methyltransferase Others
    GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3, with a Ki of 14 nM and an IC50 of 130 nM .
    GSK2807 Trifluoroacetate
  • HY-120464
    PF-05212377

    SAM-760

    		 5-HT Receptor Neurological Disease
    PF-05212377 (SAM-760) is an inhibitor for serotonin receptor 5-HT6. PF-05212377 is a substrate for P-gp/non-BCRP human transporter. PF-05212377 exhibits blood brain barrier permeability in non-human primates. PF-05212377 can be used for Alzheimer’s Disease research .
    PF-05212377
  • HY-15646
    UNC1999
    10+ Cited Publications

    		 Histone Methyltransferase Autophagy Cancer
    UNC1999 is a SAM-competitive, potent and selective inhibitor of EZH2/1 with IC50s of <10 nM and 45 nM, repectively.
    UNC1999
  • HY-129143
    Delphinidin-3-sambubioside chloride

    Dp3‐Sam chloride

    		 Apoptosis Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride
  • HY-104009
    GSK2807

    		Histone Methyltransferase Cancer
    GSK2807 is a potent and selective SAM-competitive inhibitor of SMYD3, exhibiting a Ki value of 14 nM, and it may be useful for cancer treatment by preventing the methylation of MEKK2.
    GSK2807
  • HY-119736
    Leptolstatin

    		Others Others
    Leptolstatin is an inhibitor of the progression of G1 and G2 phases of the mammalian cell cycle. Leptolstatin can be extracted from the fermentation broth of Streptomyces sp. SAM1595 .
    Leptolstatin
  • HY-162110A
    (S)-AM-9022

    		Kinesin Microtubule/Tubulin Drug Isomer Cancer
    (S)-AM-9022 is the S-enantiomer of AM-9022 (HY-162110). AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer .
    (S)-AM-9022
  • HY-118416
    BMS-986124

    		Opioid Receptor Neurological Disease
    BMS-986124 is a μ-opioid receptor silent allosteric modulator (μ-SAMs). BMS-986124 antagonizes positive allosteric modulator effect of BMS-986122 (µ-OR PAM) .
    BMS-986124
  • HY-129143R
    Delphinidin-3-sambubioside chloride (Standard)

    		Others Metabolic Disease Inflammation/Immunology
    Delphinidin-3-sambubioside (chloride) (Standard) is the analytical standard of Delphinidin-3-sambubioside (chloride). This product is intended for research and analytical applications. Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L. .
    Delphinidin-3-sambubioside chloride (Standard)
  • HY-134309
    NSC 288387

    		Virus Protease Infection
    NSC 288387 is a pan-flavivirus MTase inhibitor. NSC 288387 binds to the SAM-binding pocket. NSC 288387 inhibits ZIKV with an IC50 of 0.2 μM. NSC 288387 also inhibits viral replication in cell culture .
    NSC 288387
  • HY-100846
    JQEZ5
    3 Publications Verification

    		 Histone Methyltransferase Cancer
    JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitively inhibits polycomb repressive complex 2 (PRC2) with an IC50 of 80 nM. JQEZ5 has anti-tumor effects .
    JQEZ5
  • HY-170771
    α5-GABAA receptor modulator 1

    		GABA Receptor Neurological Disease
    α5-GABAA receptor modulator 1 (Compound A-4) is a silencing allosteric modulator (SAM) specifically targeting the a5 subunit of the GABAA receptor, suitable for research into central nervous system (CNS) disorders .
    α5-GABAA receptor modulator 1
  • HY-131493
    PF-06939999

    PRMT5-IN-3

    		 Histone Methyltransferase Apoptosis Cancer
    PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC50 in A427 is 1.1 nM), exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents .
    PF-06939999
  • HY-123689S
    Samidorphan-d4

    ALKS-33-d4; RDC-0313-d4

    		 Isotope-Labeled Compounds Neurological Disease
    Samidorphan-d4 is the deuterium labeled Samidorphan(HY-123689).Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .
    Samidorphan-d4
  • HY-123689
    Samidorphan

    ALKS-33; RDC-0313

    		 Opioid Receptor Neurological Disease
    Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo .
    Samidorphan
  • HY-123689A
    Samidorphan hydrochloride

    ALKS-33 hydrochloride; RDC-0313 hydrochloride

    		 Opioid Receptor Neurological Disease
    Samidorphan hydrochloride is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan hydrochloride acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan hydrochloride primarily acts as an opioid receptor antagonist in vivo .
    Samidorphan hydrochloride
  • HY-116708
    DCE_254

    		Histone Methyltransferase Cancer
    DCE_254 is an EZH2 inhibitor (IC50=11 μM) that also exhibits significant antiproliferative activity against lymphoma cell lines. DCE_254 inhibits the development of hypermethylation-related cancers by inhibiting the SAM-mediated methyl transfer process (IC50=10.3 μM) .
    DCE_254
  • HY-E70081
    mRNA Cap 2'-O-methyltransferase

    		Biochemical Assay Reagents Others
    mRNA Cap 2'-O-methyltransferase uses S-adenosylmethionine (SAM) as a methyl donor to add a methyl group at the 2'-O position of the first nucleotide at the 5’ end of Cap-0 mRNA, resulting in Cap-1 structure. Cap-1 structure promotes translation efficiency, increasing subsequent protein expression .
    mRNA Cap 2'-O-methyltransferase
  • HY-115514A
    BRK inhibitor P21d hydrochloride

    		BRK Cancer
    BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC50 of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC50 of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models .
    BRK inhibitor P21d hydrochloride
  • HY-P2269
    MAIT-203

    		Drug Derivative Cancer
    MAIT-203, a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 binds APC-ARM with a Ki of 0.015 μM and a Kd of 0.036 μM. MAIT-203 significantly represses the migration and invasion of colorectal cancer cells.
    MAIT-203
  • HY-P2269A
    MAIT-203 acetate

    		Drug Derivative Cancer
    MAIT-203 acetate is a cyclopentyalanin-derived peptidomimetic, potently inhibits the interaction of adenomatous polyposis coli (APC) and Asef (RhoGEF4), but not APC-Sam68 or APC-striatin interactions. MAIT-203 acetate binds APC-ARM with a Ki value of 0.015 μM and aKd value of 0.036 μM. MAIT-203 acetate significantly represses the migration and invasion of colorectal cancer cells .
    MAIT-203 acetate
  • HY-128717C
    GSK3368715 hydrochloride

    EPZ019997 hydrochloride

    		 Histone Methyltransferase Cancer
    GSK3368715 (EPZ019997) hydrochloride is an orally active, reversible, SAM-noncompetitive type I protein arginine methyltransferase (PRMT) inhibitor with IC50 values of 3.1 nM (PRMT1), 48 nM (PRMT3), 1148 nM (PRMT4), 5.7 nM (PRMT6), and 1.7 nM (PRMT8). GSK3368715 hydrochloride induces a shift in arginine methylation states, alters exon usage, and exhibits potent anticancer activity .
    GSK3368715 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: